New study tracks Real-World use of entyvio in over 1,100 ulcerative colitis patients
NCT ID NCT03824561
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at the long-term safety and effectiveness of vedolizumab (Entyvio) in over 1,100 people with moderate to severe ulcerative colitis who had not responded well to other treatments. Researchers tracked side effects and how well the drug controlled disease activity in everyday medical practice. The goal was to see how the drug performs outside of strict clinical trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vedolizumab (Entyvio)
- What this could lead to
- If successful, this confirms vedolizumab as a safe and effective long-term option for controlling moderate to severe ulcerative colitis.
- What could go wrong
- This is an observational surveillance study, not a controlled trial, so results may be less definitive. Side effects are possible, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Selected Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?